Lisa Barroilhet

Lisa Barroilhet


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2018 in Cancers
Verified
Journal Article
Open access
PDF file
ANAmruta P. Nayak
Amruta P. Nayak
AKArvinder Kapur
Arvinder Kapur
LBLisa Barroilhet
Lisa Barroilhet
Manish PatankarManish Patankar
Manish Patankar
Aerobic glycolysis is an important metabolic adaptation of cancer cells. There is growing evidence that oxidative phosphorylation is also an active metabolic pathway in many tumors, including in high grade serous ovarian cancer. Metastasized ovarian tumors use fatty acids for their energy needs. There is also evidence of ovarian cancer stem cells privileging oxidative phosphorylation (OXPHOS) for their metabolic needs. Metformin and thiazolidinediones such as rosiglitazone restrict tumor growth by inhibiting specific steps in the mitochondrial electron transport chain. These observations suggest that strategies to interfere with oxidative phosphorylation should be considered for the treatment of ovarian tumors. Here, we review the literature that supports this hypothesis and describe potential agents and critical control points in the oxidative phosphorylation pathway that can be targeted using small molecule agents. In this review, we also discuss potential barriers that can reduce the efficacy of the inhibitors of oxidative phosphorylation.

5 May 2022 in Cancers
Verified
Journal Article
Open access
PDF file
AKArvinder Kapur
Arvinder Kapur
PMPooja Mehta
Pooja Mehta
ASAaron Simmons
Aaron Simmons
SESpencer Snyder Ericksen
Spencer Snyder Ericksen
Geeta MehtaGeeta Mehta
Geeta Mehta
LBLisa Barroilhet
Lisa Barroilhet
Oxidative phosphorylation is an active metabolic pathway in cancer. Atovaquone is an oral medication that inhibits oxidative phosphorylation and is FDA-approved for the treatment of malaria. We investigated its potential anti-cancer properties by measuring cell proliferation in 2D culture. The clinical formulation of atovaquone, Mepron, was given to mice with ovarian cancers to monitor its effects on tumor and ascites. Patient-derived cancer stem-like cells and spheroids implanted in NSG mice were treated with atovaquone. Atovaquone inhibited the proliferation of cancer cells and ovarian cancer growth in vitro and in vivo. The effect of atovaquone on oxygen radicals was determined using flow and imaging cytometry. The oxygen consumption rate (OCR) in adherent cells was measured using a Seahorse XFe96 Extracellular Flux Analyzer. Oxygen consumption and ATP production were inhibited by atovaquone. Imaging cytometry indicated that the majority of the oxygen radical flux triggered by atovaquone occurred in the mitochondria. Atovaquone decreased the viability of patient-derived cancer stem-like cells and spheroids implanted in NSG mice. NMR metabolomics showed shifts in glycolysis, citric acid cycle, electron transport chain, phosphotransfer, and metabolism following atovaquone treatment. Our studies provide the mechanistic understanding and preclinical data to support the further investigation of atovaquone’s potential as a gynecologic cancer therapeutic.

1 June 2023 in Radiology
Verified
Journal Article
Closed access
ESElizabeth A. Sadowski
Elizabeth A. Sadowski
ARAnd Andrea G. Rockall
And Andrea G. Rockall
ITIsabelle Thomassin-Nagarra
Isabelle Thomassin-Nagarra
LBLisa Barroilhet
Lisa Barroilhet
SWSumer K. Wallace
Sumer K. Wallace
CRCaroline Reinhold
Caroline Reinhold
Currently, imaging is part of the standard of care for patients with adnexal lesions prior to definitive management. Imaging can identify a physiologic finding or classic benign lesion that can be followed up conservatively. When one of these entities is not present, imaging is used to determine the probability of ovarian cancer prior to surgical consultation. Since the inclusion of imaging in the evaluation of adnexal lesions in the 1970s, the rate of surgery for benign lesions has decreased. More recently, data-driven Ovarian-Adnexal Reporting and Data System (O-RADS) scoring systems for US and MRI with standardized lexicons have been developed to allow for assignment of a cancer risk score, with the goal of further decreasing unnecessary interventions while expediting the care of patients with ovarian cancer. US is used as the initial modality for the assessment of adnexal lesions, while MRI is used when there is a clinical need for increased specificity and positive predictive value for the diagnosis of cancer. This article will review how the treatment of adnexal lesions has changed due to imaging over the decades; the current data supporting the use of US, CT, and MRI to determine the likelihood of cancer; and future directions of adnexal imaging for the early detection of ovarian cancer.

1 March 2018 in Gynecologic Oncology
Verified
Journal Article
Closed access
LBLisa Barroilhet
Lisa Barroilhet
UMUrsula Matulonis
Ursula Matulonis

1 June 2022 in Radiology
Verified
Journal Article
Closed access
AGA G
A G
PJPriyanka Jha
Priyanka Jha
TBTimothy M. Baran
Timothy M. Baran
KMKatherine E. Maturen
Katherine E. Maturen
KPKrupa Patel-Lippmann
Krupa Patel-Lippmann
ESElizabeth Sadowski
Elizabeth Sadowski
In women at average risk for ovarian cancer, assessing isolated adnexal lesions as classic- versus nonclassic-appearing at US had high sensitivity and specificity, similar to published risk stratif... Background Several US risk stratification schemas for assessing adnexal lesions exist. These multiple-subcategory systems may be more multifaceted than necessary for isolated adnexal lesions in ave...

15 May 2018 in Gynecologic Oncology
Verified
Journal Article
Closed access
PDF file
AOAndrea O'Shea
Andrea O'Shea
KMKevin McCool
Kevin McCool
RHRoss Harrison
Ross Harrison
ESEmmanuel Sampene
Emmanuel Sampene
JCJoseph Connor
Joseph Connor
LBLisa Barroilhet
Lisa Barroilhet